Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antibiotics Go Head-To-Head In PCORI-Funded Observational Study

Executive Summary

Patient-Centered Outcomes Research Institute selected five drug-related research topics for funding, including a look at narrow- versus broad-spectrum antibiotics for acute respiratory tract infections in children, though all studies are observational. PCORI approved 52 CER projects in this third funding round, including many declined in the first round.

You may also be interested in...



Antibiotic Resistance Gets Attention Of FDA, Congress

Both FDA and Congress are taking interest in combating antibiotic resistance, but FDA likely has more power to make headway in the near term, even as industry remains somewhat wary of that particular agenda item.

Inflammatory Bowel Drugs To Go Head-To-Head With PCORI Funding

A number of drug-related comparative effectiveness research projects are approved for PCORI-sponsored research in its second funding cycle. Health IT-related projects also get attention as the institute spends more than $88 million on 51 projects.

With PCORI Methods Approved, Attention Shifts To Implementation

At its November meeting, the Patient-Centered Outcomes Research Institute’s board of governors approves revisions to the methodological standards for patient-centered outcomes research found in the Methodology Committee report. The board also begins a dialogue on how the standards will be integrated into the funding and research process.

Related Content

Topics

UsernamePublicRestriction

Register

PS055602

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel